Dr LeVee on Breast Cancer Presentations to Watch at the 2026 ASCO Annual Meeting

“They’re doing an analysis of the ASCENT-03 and ASCENT-04 trials [investigating] sacituzumab govitecan with or without pembrolizumab [and] how the biomarkers could predict response for that. I am looking to see whether we could use biomarkers to predict who would benefit from those therapies.”

Alexis Ann LeVee, MD, a breast medical oncologist at UCLA Health, discussed breast cancer topics of interest to watch for at the 2026 ASCO Annual Meeting.

LeVee highlighted several potentially practice-informing abstracts within the breast cancer field that are being presented at ASCO 2026, particularly noting the integration of novel immunotherapies and antibody-drug conjugates. She spotlighted the phase 2 I-SPY 2.2 trial (NCT01042379), a portion of which is investigating neoadjuvant rilvegostomig—a bispecific antibody targeting both PD-1 and TIGIT—combined with fam-trastuzumab deruxtecan-nxki (Enhertu) in patients with high-risk, HER2-negative breast cancer. Findings from this portion of the trial will be presented on June 1, 2026, at 10:45am CT.

Additionally, she observed the potential clinical implications of the upcoming time to second progression data update from the phase 3 SERENA-6 trial (NCT04964934), which evaluated switching to camizestrant upon emergence of an ESR1 mutation during treatment with an aromatase inhibitor and a CDK4/6 inhibitor ahead of radiographic disease progression in patients with hormone receptor–positive, HER2-negative metastatic breast cancer. Findings from this data update will be presented on June 2, 2026, at 11:57 am CT.

She also emphasized how biomarker analyses from the phase 3 ASCENT-03 (NCT05382299) and ASCENT-04 (NCT05382286) trials may refine treatment protocols in the future. These trials are evaluating sacituzumab govitecan-hziy (Trodelvy) as monotherapy and in combination with pembrolizumab (Keytruda), respectively, in patients with previously untreated metastatic triple-negative breast cancer. According to LeVee, these findings will be critical for determining whether specific biomarkers can accurately predict patient response. Ultimately, she concluded that these studies represent a shift toward using data to identify which patient populations may derive the greatest benefit from advanced therapies. Findings from these analyses will be presented on May 31, 2026, starting at 11:30 am CT.